Please provide your email address to receive an email when new articles are posted on . Briquilimab depletes the mast cells that release inflammatory mediators. Patients reported improvements in ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...

Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and immunotherapy may be able to follow a watch-and-wait protocol. Without ...

Pathologic complete response shows poor surrogacy for overall survival (OS) in neoadjuvant breast cancer (BC) trials, while invasive disease-free survival demonstrates moderate to strong association ...

CG Oncology, Inc. (NASDAQ:CGON) announced on Saturday that cretostimogene grenadenorepvec monotherapy data were presented at the 2025 American Urological Association Annual Meeting. The Phase 3 ...

Patients with metastatic urothelial carcinoma who achieved a complete response after more than 8.5 months of single-agent enfortumab vedotin (Padcev) were able to be off treatment for over 2 years ...

FDA rejection was attributed to a lack of substantial evidence of efficacy, including inconsistencies that undermined confidence in reproducibility across investigations. Reproxalap targets reactive ...

WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group (REPL), Inc. , a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...

NOVATO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE), today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat ...